Further, the overexpression of METTL3 increased RP11 expression in the CRC cells, suggesting m6A-induced RP11 expression promotes CRC progression and is likely a potential biomarker and a novel therapeutic target for CRC [47]. Here, METTL3 is linked to colorectal carcinoma.